However, because hypereosinophilia is insufficient to cause pathology without extravascular migration and activation, our findings raise the question of whether dual blockade of eosinophils and IL-33 or IL4Rα could be useful for therapy in EGPA. This evidence concerns the gene IL33 and eosinophilic granulomatosis with polyangiitis.